Avid Bioservices Inc (CDMO)

[entdoc]

firefox, thanks. I think we are in agreement, and I think I have a fair understand the "micro" MOA of Bavi, which is what I posted about the last couple days--chemokines and all that--and which I thought you posted that we should not get bogged down about.
I can't agree that the double-armed model works as well with one of the arms tied behind its back, so to speak. We know that VEGFs (Avastin) destroy tumor vasculature too, as does anti-PS, but it is the residual cancer cells that I think should also be addressed, especially in immunocompromised patients.